Sun Pharmaceutical Industries Limited — Important, 02-02-2026: Updates

Sun Pharma reported robust FY25 performance with ₹85,462.9 Cr revenue & ₹10,929 Cr profit. ESG strides include 21% Scope 1&2 emissions cut, 25% water reduction (exceeding targets), and 41% renewable energy. R&D investments hit ₹3,250 Cr. Operational integrity remained high, with only minor recalls and no significant compliance issues.